Cargando…
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study
OBJECTIVE: Infection is a major cause of death in patients with SLE. This study aimed to explore the infection rate in patients with SLE receiving a low dose of intravenous cyclophosphamide (IV-CYC). METHODS: Clinical parameters of 1022 patients with SLE from 24 hospitals in China were collected. Pa...
Autores principales: | Shao, Miao, Miao, Miao, Zhang, Xia, Zhang, Xiaoying, An, Yuan, Guo, Huifang, Lei, Lingyan, Zhao, Qing, Ding, Yanjie, Lin, Jin, Wu, Rui, Yu, Feng, Li, Yucui, Miao, Huali, Zhang, Liyun, Du, Yan, Jiao, Ruiying, Pang, Lixia, Long, Li, Yao, Xueming, Shi, Xiaofei, Wang, Fei, Cui, Luping, Zhang, Lei, Liu, Shengyun, Lu, Fuai, Luo, Kangkai, Zhao, Simeng, Wang, Yongfu, Wu, Xiao, Wang, Qingwen, Liu, Hongjiang, Song, Shulin, Zhou, Xiaoyuan, Zhang, Xiaoping, Shi, Shumei, Zhu, Hong, Chen, Yao, Yu, Honglian, Wu, Jie, Yu, Ruiyun, Fan, Wenqiang, Liu, Shuang, Xu, Jian, Chen, Zhibin, Shi, Lianjie, He, Jing, Zhang, Xuewu, Li, Zhanguo, Li, Ru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644361/ https://www.ncbi.nlm.nih.gov/pubmed/36351697 http://dx.doi.org/10.1136/lupus-2022-000779 |
Ejemplares similares
-
Toll-Like Receptors Expressed by Synovial Fibroblasts Perpetuate Th1 and Th17 Cell Responses in Rheumatoid Arthritis
por: Hu, Fanlei, et al.
Publicado: (2014) -
Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
por: Miao, Miao, et al.
Publicado: (2020) -
Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study
por: Miao, Miao, et al.
Publicado: (2021) -
Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE
por: Zhou, Haotian, et al.
Publicado: (2023) -
Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model
por: Zhang, Miao, et al.
Publicado: (2023)